Indapta Therapeutics

Indapta Therapeutics is a private, clinical-stage biotech harnessing a unique subset of natural killer cells, known as G-NK cells, for off-the-shelf cellular immunotherapy. Founded in 2018, the company is advancing its platform into Phase 1 trials for hematologic cancers (in combination with monoclonal antibodies) and multiple sclerosis. With backing from prominent venture capital firms and a seasoned leadership team, Indapta aims to address significant limitations in current autologous cell therapies and autoimmune disease treatments.

Proprietary platform for expanding allogeneic, off-the-shelf, FcRγ-deficient natural killer (G-NK) cells, a naturally occurring subset with enhanced antibody-dependent cellular cytotoxicity (ADCC) and cytolytic activity for treating cancer and autoimmune diseases.

Indapta competes in the rapidly growing allogeneic NK/CAR-NK cell therapy space against companies like Nkarta, Fate Therapeutics, and Century Therapeutics. Its primary differentiation is the use of non-engineered, naturally potent G-NK cells, avoiding potential risks of genetic modification and targeting both oncology and autoimmunity.